作者
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru, Barbara Biedrzycki, Ross C Donehower, Atif Zaheer, George A Fisher, Todd S Crocenzi, James J Lee, Steven M Duffy, Richard M Goldberg, Albert De La Chapelle, Minori Koshiji, Feriyl Bhaijee, Thomas Huebner, Ralph H Hruban, Laura D Wood, Nathan Cuka, Drew M Pardoll, Nickolas Papadopoulos, Kenneth W Kinzler, Shibin Zhou, Toby C Cornish, Janis M Taube, Robert A Anders, James R Eshleman, Bert Vogelstein, Luis A Diaz Jr
发表日期
2015/6/25
期刊
New England Journal of Medicine
卷号
372
期号
26
页码范围
2509-2520
出版商
Massachusetts Medical Society
简介
Background
Somatic mutations have the potential to encode “non-self” immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade.
Methods
We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti–programmed death 1 immune checkpoint inhibitor, in 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency. Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with mismatch repair–deficient colorectal cancers, patients with mismatch repair–proficient colorectal cancers, and patients with mismatch repair–deficient cancers that were not colorectal. The coprimary end points were the immune-related objective response rate and the 20-week immune-related …
学术搜索中的文章
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling… - New England Journal of Medicine, 2015